Costco Wholesale will pay $11.75 million to resolve claims that some of its pharmacies filled improper or incomplete prescriptions for controlled substances » Read More
Walgreens settles U.S. lawsuit that accuses company of incentivizing the fulfillment of government healthcare prescriptions. » Read More
Mallinckrodt has agreed to pay $100 million to settle allegations that it broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug. » Read More
A trial has shown that a non-surgical method of treatment for low-risk prostate cancer can kill cancer cells and preserve healthy tissue.
"Fast Money" trader David Seaburg pitches to the desk why to buy under-the-radar biotech stock AbbVie.
CNBC's Meg Tirrell speaks to new Biogen CEO Michel Vounatsos about the outlook of the company, Eli Lilly's experimental Alzheimer's drug and his expectations of the Trump administration.
After a five-month search, Biogen names Michel Vounatsos its next CEO. CNBC's Meg Tirrell reports.
Jefferies lowers its 2017 Merck earnings-per-share estimate to $3.69 from $4.14.
Clovis Oncology shares jumped 15 percent Monday after the FDA approved Rubraca (rucaparib), the company's advanced ovarian cancer drug.
CNBC's Meg Tirrell reports on the launch of Mylan's "authorized generic" version of their EpiPen.
Morgan Stanley expects Eli Lilly's sales will rise by 5 percent a year through 2020.
Donald Trump is likely to go after a short list of drug companies in his vow to bring prices down, says Jake Novak.
Mylan said on Friday it launched the generic version of its life-saving EpiPen allergy treatment at a more than 50 percent discount.
Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.
Actavis UK broke competition law by raising prices of hydrocortisone tablets by more than 12,000 percent, UK's competition watchdog said.
These are the stocks posting the largest moves after the bell, including Oracle, Agio Pharmaceuticals, Adobe and more.
Papa said he would consider selling some of Valeant's core businesses and assets against the wishes of some of its major shareholders.
Valeant's Joseph Papa spoke exclusively with CNBC about the state of drug pricing, and what could be ahead for the company.
Valeant CEO Joseph Papa speaks with CNBC's Kelly Evans at the Yale CEO Summit about his outlook for 2017 and the environment for drug pricing under President-elect Trump.
Get the best of CNBC in your inbox